Relation of short-latency afferent inhibition to the cholinergic system

Completed

Conditions: hypokinetic rigid syndrome
Parkinson's disease
10028037
10009841

Registration Number: NL-OMON49949

Lead Sponsor: niversitair Medisch Centrum Groningen

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: Completed

Sex: Not specified

Target Recruitment: 40

Inclusion Criteria

- Willingness to cooperate and sign written informed consent
Patients:
- Clinical diagnosis of idiopathic Parkinson*s disease by a neurologist.

Exclusion Criteria

- Incapable to provide informed consent
- Treatment with anticholinergics
- Current or recent treatment with ChEIs
- Presence of deep brain stimulation implants
- (Suspected) pregnancy
- Migraine
- Epilepsy
- Participation in a scientific research study during the past year involving
radiation
- MRI contra-indications, e.g.
o Ferrous objects in or around the body (e.g. braces, pacemaker, metal
fragments)
o Claustrophobia
- Insufficient knowledge of the Dutch language
Control subjects:
- History of neurological or neurodegenerative disorder
Parkinson Disease Dementia:
- Unsafe or irresponsible to postpone treatment with cholinesterase inhibitor,
according to treatment provider

Study & Design

Study Type: Observational invasive

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>The main study parameter resulting from the SAI-measurement is percentage of<br /><br>conditioned motor evoked potential (MEP) versus unconditioned MEP. The main<br /><br>study parameter resulting from [18F]FEOBV PET imaging is the mean cortical<br /><br>tracer binding. We will perform a correlation analysis between these parameters<br /><br>as a main outcome measure.</p><br>

Secondary Outcome Measures

Name	Time	Method
<p>- Tracer binding in different ROIs and per voxel.<br /><br>- Outcome of all questionnaires and clinical tests as mentioned under E4.<br /><br>- Resting-state functional connectivity.</p><br>